Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 153

1.

Long-acting depot formulations of naltrexone for heroin dependence: a review.

Krupitsky EM, Blokhina EA.

Curr Opin Psychiatry. 2010 May;23(3):210-4. doi: 10.1097/YCO.0b013e3283386578. Review.

PMID:
20224403
2.

Depot naltrexone: antagonism of the reinforcing, subjective, and physiological effects of heroin.

Sullivan MA, Vosburg SK, Comer SD.

Psychopharmacology (Berl). 2006 Nov;189(1):37-46. Epub 2006 Sep 14.

PMID:
16972105
3.

Naltrexone depot formulations for opioid and alcohol dependence: a systematic review.

Lobmaier PP, Kunøe N, Gossop M, Waal H.

CNS Neurosci Ther. 2011 Dec;17(6):629-36. doi: 10.1111/j.1755-5949.2010.00194.x. Review.

PMID:
21554565
4.

Long-acting injectable versus oral naltrexone maintenance therapy with psychosocial intervention for heroin dependence: a quasi-experiment.

Brooks AC, Comer SD, Sullivan MA, Bisaga A, Carpenter KM, Raby WM, Yu E, O'Brien CP, Nunes EV.

J Clin Psychiatry. 2010 Oct;71(10):1371-8. doi: 10.4088/JCP.09m05080ecr. Epub 2010 Jul 13.

5.

Long-acting injectable naltrexone for the treatment of alcohol dependence.

Mannelli P, Peindl K, Masand PS, Patkar AA.

Expert Rev Neurother. 2007 Oct;7(10):1265-77. Review.

PMID:
17939765
6.

Injectable extended-release naltrexone (XR-NTX) for opioid dependence: long-term safety and effectiveness.

Krupitsky E, Nunes EV, Ling W, Gastfriend DR, Memisoglu A, Silverman BL.

Addiction. 2013 Sep;108(9):1628-37. doi: 10.1111/add.12208. Epub 2013 May 24.

PMID:
23701526
7.

Efficacy and tolerability of naltrexone in the treatment of alcohol dependence: oral versus injectable delivery.

Roozen HG, de Waart R, van den Brink W.

Eur Addict Res. 2007;13(4):201-6.

PMID:
17851241
8.

Risk factors for craving and relapse in heroin users treated with oral or implant naltrexone.

Hulse GK, Ngo HT, Tait RJ.

Biol Psychiatry. 2010 Aug 1;68(3):296-302. doi: 10.1016/j.biopsych.2010.04.003. Epub 2010 May 26.

PMID:
20537615
9.

Blame the counselling, not the implant. A response to Oliver, Horspool & Keen (2005).

Kunøe N, Lobmaier P.

Addiction. 2005 Jul;100(7):1027-8; author reply 1028-9. No abstract available.

PMID:
15955020
10.

Single- and multiple-dose pharmacokinetics of long-acting injectable naltrexone.

Dunbar JL, Turncliff RZ, Dong Q, Silverman BL, Ehrich EW, Lasseter KC.

Alcohol Clin Exp Res. 2006 Mar;30(3):480-90.

PMID:
16499489
11.

Depot naltrexone: long-lasting antagonism of the effects of heroin in humans.

Comer SD, Collins ED, Kleber HD, Nuwayser ES, Kerrigan JH, Fischman MW.

Psychopharmacology (Berl). 2002 Feb;159(4):351-60. Epub 2001 Nov 1.

13.

Maintenance treatment with depot opioid antagonists in subcutaneous implants: an alternative in the treatment of opioid dependence.

Carreño JE, Alvarez CE, Narciso GI, Bascarán MT, Díaz M, Bobes J.

Addict Biol. 2003 Dec;8(4):429-38.

PMID:
14690879
15.

Improving clinical outcomes in treating heroin dependence: randomized, controlled trial of oral or implant naltrexone.

Hulse GK, Morris N, Arnold-Reed D, Tait RJ.

Arch Gen Psychiatry. 2009 Oct;66(10):1108-15. doi: 10.1001/archgenpsychiatry.2009.130.

PMID:
19805701
16.

Improvement in naltrexone treatment compliance with contingency management.

Preston KL, Silverman K, Umbricht A, DeJesus A, Montoya ID, Schuster CR.

Drug Alcohol Depend. 1999 Apr 1;54(2):127-35.

PMID:
10217552
17.

Naltrexone implants as treatment for heroin dependence: part I.

Byrne A, Graham G, Hallinan R, Murnion B.

Addict Biol. 2005 Jun;10(2):201; author reply 201-2. No abstract available.

PMID:
16191674
18.

A possible role for implantable naltrexone in the management of the high-risk pregnant heroin user.

Hulse GK, O'Neill G.

Aust N Z J Obstet Gynaecol. 2002 Feb;42(1):93-4. No abstract available.

PMID:
11926651
19.

Naltrexone implants as treatment for heroin dependence: part II.

Wodak A, Graham R.

Addict Biol. 2005 Jun;10(2):202; author reply 202-4. No abstract available.

PMID:
16201030
20.

Precipitated withdrawal during maintenance opioid blockade with extended release naltrexone.

Fishman M.

Addiction. 2008 Aug;103(8):1399-401. doi: 10.1111/j.1360-0443.2008.02252.x.

PMID:
18855831

Supplemental Content

Support Center